Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.
Lyell Immunopharma reports developments tied to its next-generation chimeric antigen receptor, or CAR T-cell, therapy pipeline for patients with cancer. The company’s recurring updates center on ronde-cel, an autologous dual-targeting CD19/CD20 CAR T-cell product candidate for large B-cell lymphoma, and LYL273, a GCC-targeted CAR T-cell product candidate for metastatic colorectal cancer and other GCC-expressing cancers.
Company news also covers clinical-trial activity, FDA designation updates, manufacturing capabilities at the LyFE Manufacturing Center, quarterly financial results, equity financing activity, licensing transactions, investor-conference participation and executive or governance changes.
Summary not available.
Summary not available.
Summary not available.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) reported financial results for Q4 and full year 2022, highlighting a net loss of $8.4 million for Q4 and $183.1 million for the year, but significantly increased revenue of $48.4 million for Q4 and $84.7 million for the year, up from $2.8 million and $10.7 million in 2021. The company's cash position stands at $710.3 million as of December 31, 2022, supporting ongoing clinical trials and a robust pipeline. Lyell initiated Phase 1 trials for two product candidates targeting solid tumors and presented promising nonclinical data at several conferences. The company expects initial clinical data from LYL797 and LYL845 in 2024.
Lyell Immunopharma will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10 at 4:30 pm PT. The presentation will showcase Lyell's pipeline, including CAR T cell product candidates LYL797 and LYL845, both in Phase 1 trials, and the innovative LYL119 targeting ROR1. Key technologies will be highlighted, such as NR4A3 gene knockout and Stim-RTM for enhanced CAR T cell activity. A live webcast will be available on the company’s website with a 30-day replay.
Lyell Immunopharma (Nasdaq: LYEL) has appointed Lynn Seely, MD, as president & CEO, succeeding Liz Homans, who transitions to a consulting role until June 2024. Dr. Seely brings extensive biopharmaceutical leadership experience, having previously served as CEO of Myovant Sciences, where she successfully launched therapies for cancer and women's health. Under her leadership, Lyell aims to advance its clinical-stage programs and enhance its T-cell reprogramming technologies to improve treatment outcomes for solid tumors.
Lyell Immunopharma (Nasdaq: LYEL) is set to participate in the BofA Securities 2022 Biotech SMID Cap Conference on December 8, 2022, at 1:40 pm ET. The event will feature members of its senior management team, and a live webcast will be available on the company's website. This opportunity highlights Lyell's commitment to developing curative cell therapies for solid tumors, leveraging proprietary technologies to overcome key barriers in adoptive T-cell therapy. A replay of the webcast will be accessible for 90 days post-event.
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company, announced participation in the Barclays Virtual Fireside Chat Series on November 17 at 11 a.m. ET. The event will feature senior management discussing advancements in curative cell therapies for solid tumors. A webcast of the presentation can be accessed on the company's investor relations website, with a replay available for 90 days afterwards. Lyell focuses on overcoming challenges in adoptive T-cell therapy through innovative genetic and epigenetic reprogramming technologies.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced FDA clearance of the IND for LYL845, advancing its TIL product candidate into clinical development. As of September 30, 2022, the company reported cash equivalents of $750.7 million, extending its financial runway into 2026. Revenue dipped to approximately zero in Q3 2022, down from $2.8 million in Q3 2021, reflecting no R&D under the GSK Agreement. The net loss increased to $70.3 million compared to $48.9 million year-over-year. Lyell is expected to present initial data for LYL845 in 2024.
Lyell Immunopharma (Nasdaq: LYEL) is presenting preclinical research at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, showcasing advancements in T-cell therapies targeting solid tumors. Key highlights include:
- LYL845 exhibits a 100% expansion success rate using Epi-R technology.
- Research indicates LYL845 maintains T-cell polyclonality and stem-like properties, enhancing anti-tumor efficacy.
- Innovative stackable reprogramming technologies are being developed for LYL119 to improve CAR T-cell therapies.
These findings aim to address T-cell exhaustion and enhance treatment outcomes in cancer patients.